Some of these molecules were also effective in other MDS yeast models, in particular those characterized by mutations in MIP1 and RNR2, orthologs of the human genes POLG and RRM2B respectively, potentially expanding their application to a wider range of MDS patients. The gene discussed is RRM2B; the disease is myelodysplastic syndrome.